
==== Front
Front Neurosci
Front Neurosci
Front. Neurosci.
Frontiers in Neuroscience
1662-4548
1662-453X
Frontiers Media S.A.

10.3389/fnins.2021.693404
Neuroscience
Review
Role of the Dopaminergic System in the Striatum and Its Association With Functional Recovery or Rehabilitation After Brain Injury
Verduzco-Mendoza Antonio 12

Carrillo-Mora Paul 3

Avila-Luna Alberto 3

Gálvez-Rosas Arturo 3
Olmos-Hernández Adriana 2
Mota-Rojas Daniel 4
Bueno-Nava Antonio 3*

1Ph.D. Program in Biological and Health Sciences, Universidad Autónoma Metropolitana, Mexico City, Mexico
2Division of Biotechnology-Bioterio and Experimental Surgery, Instituto Nacional de Rehabilitación-Luis Guillermo Ibarra Ibarra, Mexico City, Mexico
3Division of Neurosciences, Instituto Nacional de Rehabilitación-Luis Guillermo Ibarra Ibarra, Mexico City, Mexico
4Neurophysiology, Behavior and Animal Welfare Assessment, DPAA, Universidad Autónoma Metropolitana, Mexico City, Mexico
Edited by: Santiago Perez-Lloret, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina

Reviewed by: Yoland Smith, Emory University, United States; Harumasa Takano, National Center of Neurology and Psychiatry, Japan

*Correspondence: Antonio Bueno-Nava, abueno@inr.gob.mx; ton631@hotmail.com
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience

24 6 2021
2021
15 69340410 4 2021
03 6 2021
Copyright © 2021 Verduzco-Mendoza, Carrillo-Mora, Avila-Luna, Gálvez-Rosas, Olmos-Hernández, Mota-Rojas and Bueno-Nava.
2021
Verduzco-Mendoza, Carrillo-Mora, Avila-Luna, Gálvez-Rosas, Olmos-Hernández, Mota-Rojas and Bueno-Nava
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Disabilities are estimated to occur in approximately 2% of survivors of traumatic brain injury (TBI) worldwide, and disability may persist even decades after brain injury. Facilitation or modulation of functional recovery is an important goal of rehabilitation in all patients who survive severe TBI. However, this recovery tends to vary among patients because it is affected by the biological and physical characteristics of the patients; the types, doses, and application regimens of the drugs used; and clinical indications. In clinical practice, diverse dopaminergic drugs with various dosing and application procedures are used for TBI. Previous studies have shown that dopamine (DA) neurotransmission is disrupted following moderate to severe TBI and have reported beneficial effects of drugs that affect the dopaminergic system. However, the mechanisms of action of dopaminergic drugs have not been completely clarified, partly because dopaminergic receptor activation can lead to restoration of the pathway of the corticobasal ganglia after injury in brain structures with high densities of these receptors. This review aims to provide an overview of the functionality of the dopaminergic system in the striatum and its roles in functional recovery or rehabilitation after TBI.

dopamine
corticostriatal pathway
functional recovery
traumatic brain injury
dopamine receptors
Consejo Nacional de Ciencia y Tecnología10.13039/501100003141CB-2016-287614 Consejo Nacional de Innovaciín, Ciencia y Tecnología10.13039/501100009068CB-2016-288512
==== Body
Introduction

Traumatic brain injury (TBI) is a main cause of disability; approximately 2% of people worldwide suffer from a TBI-related disability (Bales et al., 2009). Currently, TBI is defined as “an alteration in brain function, or other evidence of brain pathology, caused by an external force” (Menon et al., 2010). Anatomical damage, neurological deficits and mental status are common indices used to categorize TBI as mild, moderate or severe (Corrigan et al., 2010). One of the structures that is typically injured in TBI is the cerebral cortex, which is anatomically connected with other brain regions, such as the striatum, thalamus, pons and cerebellum, by afferent and efferent axons in pathways such as the corticobasal ganglia-thalamocortical and cerebellothalamocortical pathways (Daskalakis et al., 2004; Bostan and Strick, 2010; Mendoza and Merchant, 2014).

The striatum is the main input nucleus of the basal ganglia and receives glutamatergic afferents, such as motor, oculomotor, executive/associative and emotion-/motivation-related afferents, from diverse cortical areas (Reiner et al., 2010; Mathai and Smith, 2011; Kandel et al., 2013). Corticostriatal glutamatergic inputs are bilateral but have an ipsilateral predominance in the striatum (Reep et al., 2003; Lei et al., 2004; Wu et al., 2009; Reiner et al., 2010) and are critically modulated by dopamine (DA) produced by the substantia nigra pars compacta (SNc) (Bjorklund and Dunnett, 2007). TBI is associated with effects on dopaminergic transmission at the level of the striatum (Bales et al., 2009; Karelina et al., 2017; Jenkins et al., 2018; Plummer et al., 2018), such as reductions in the synthesis and release of striatal DA (Wagner et al., 2005b; Shin et al., 2011).

The literature supports the beneficial effects of dopaminergic drugs in patients with TBI, confirming that they accelerate functional recovery and rehabilitation after brain injury (Harmon and Boyeson, 1997; Bales et al., 2009; Frenette et al., 2011, 2012; Osier and Dixon, 2016a; Carrillo-Mora et al., 2017; Munakomi et al., 2017; Duong et al., 2018; Plummer et al., 2018; Loggini et al., 2020). The mechanisms of action of dopaminergic drugs administered to patients with TBI include blockade of the DA transporter (DAT), inhibition of DA reuptake and facilitation of DA synthesis, and the drugs most highly recommended by the Neurotrauma Foundation are methylphenidate (MPD), amantadine, and bromocriptine (Bales et al., 2009). However, administration of these drugs to patients with TBI is recommended only for symptomatic therapy to enhance attentional function, processing speed, and executive function (Bales et al., 2009).

The mechanisms of action of dopaminergic drugs have not been completely clarified, partly because dopaminergic receptor activation leads to restoration of neuronal circuits after injury to brain structures with high densities of these receptors. This review aims to provide an overview of the functionality of the dopaminergic system in the dorsal striatum and its role in functional recovery or rehabilitation after TBI.

Organization of the Corticostriatal Pathway

The corticostriatal pathway originates mainly in the motor and premotor cortices of the brain from pyramidal neurons located in layers V and III (Mathai and Smith, 2011). Glutamatergic cortical afferents target dendritic spines of medium spiny neurons (MSNs) in the striatum (Bolam et al., 2000; Surmeier et al., 2007; Kreitzer and Malenka, 2008; Silberberg and Bolam, 2015). In addition, the striatum receives glutamatergic afferent inputs from the thalamus, subthalamic nucleus, pedunculopontine nucleus, hippocampus, and amygdala (Smith and Parent, 1986; Doig et al., 2010; Lodge and Grace, 2011; Mathai and Smith, 2011; Koshimizu et al., 2013; Haber, 2016; Wouterlood et al., 2018; Assous et al., 2019). The main glutamatergic inputs to the MSNs are derived from the brain cortex and thalamus (Haber, 2016). Cortical inputs to the striatum are dominant with respect to thalamic inputs in terms of axonal density and synaptic interactions with MSNs (Lei et al., 2004; Smith et al., 2004; Reiner et al., 2010; Silberberg and Bolam, 2015; Haber, 2016). These corticostriatal inputs are bilateral but have an ipsilateral predominance (Reep et al., 2003; Lei et al., 2004; Wu et al., 2009; Reiner et al., 2010).

In rodents, the striatum receives corticostriatal inputs from intratelencephalic (IT) neurons and pyramidal tract (PT) neurons (Mathai and Smith, 2011; Shepherd, 2013). IT afferents are principally derived from neurons located in layer III and in upper layer V of the brain cortex (Lei et al., 2004; Mathai and Smith, 2011). In the striatum, afferent inputs from IT and PT cortical neurons target both direct and indirect pathways (Doig et al., 2010; Mathai and Smith, 2011; Silberberg and Bolam, 2015; Haber, 2016). The striatal dorsolateral area receives cortical input from the sensory-motor region, the striatal central and dorsomedial areas receive inputs from the associative cortical region, and the striatal ventromedial area receives input from the limbic region (Haber, 2016; Kupferschmidt et al., 2017).

Distribution and Function of DA Receptors

The DA receptor family includes D1-like (D1 and D5) and D2-like (D2, D3, and D4) subtypes (Bunzow et al., 1988; Sunahara et al., 1991; Van Tol et al., 1991; Missale et al., 1998; Vallone et al., 2000). In the cerebral cortex, autoradiographic localization studies have shown that both rodent and primate cortices contain D1 receptors (D1Rs) and D2 receptors (D2Rs) (Camps et al., 1990), but the density of D1Rs is 10–20-fold higher than that of D2Rs (Lidow et al., 1991). In addition, the highest ratio of mRNA expression of D1Rs compared with D2Rs is found in the prefrontal cortex (Santana and Artigas, 2017), where both D1Rs and D2Rs are expressed in glutamatergic and GABAergic neurons (Figure 1A; Santana and Artigas, 2017). As previously reported (Abekawa et al., 2000), D1R activation reduces extracellular glutamate and GABA levels in the medial prefrontal cortex. In one study, D1R activation of interneurons led to decreased activity of the corticostriatal pathway (Muly et al., 1998). Other studies have documented the localization of D1Rs in corticostriatal pyramidal neurons, while some authors reported that the effects of D2R activation are confined to type I corticopontine neurons of layer V (Gaspar et al., 1995; Leyrer-Jackson and Thomas, 2017). Similar to the case in the striatum, D2Rs in the prefrontal cortex are restricted to specific neural populations (Gee et al., 2012). In addition, D2Rs are localized in the axons of dopaminergic afferents (Bjorklund and Dunnett, 2007).

FIGURE 1 Schematic representation of the corticostriatal pathway under normal conditions (A), under conditions of cortical injury (B), and during the injury recovery process/the proposed effects of administration of dopaminergic drugs (C). For the circles, triangles and lines, red indicates excitatory projections, whereas black indicates inhibitory projections. The color orange represents the substantia nigra pars compacta (SNc). The dotted lines indicate depletion by injury in the cerebral cortex and SNc. SNr, substantia nigra pars reticulata; GPi, internal segment of the globus pallidus; GPe, external segment of the globus pallidus; STN, subthalamic nucleus.

In the striatum, a subpopulation of MSNs known as striatonigral neurons express D1-like receptors, predominantly D1Rs, at high levels (Bergson et al., 1995; Le Moine and Bloch, 1995; Surmeier et al., 1996); however, D2Rs are selectively expressed in a second subpopulation, the striatopallidal MSNs (Le Moine and Bloch, 1995; Valjent et al., 2009). Activation of pre- and postsynaptic D1Rs and D2Rs is associated with modulation of corticostriatal glutamatergic transmission and synaptic plasticity in corticostriatal synapses (Kerkerian et al., 1987; Hsu et al., 1995; López De Maturana and Sánchez-Pernaute, 2010). Functionally, striatal D1Rs and D2Rs, but not extrastriatal DA receptors, are responsible for dopaminergic motor stimulation (Wang and Zhou, 2017). As shown in our recent studies, D1R activation maintains motor coordination and balance in both normal and injured rats (Avila-Luna et al., 2018a, b).

Neuronal Death and Axonal Injury in Neural Groups After TBI

Primary injury is characterized locally by destruction of brain tissue, including neuronal and glial destruction originating from intracranial hemorrhage, epidural and subdural hematomas, brain contusions and direct mechanical injury (Eakin et al., 2013; Loane and Kumar, 2016; Lu et al., 2019; Shi et al., 2019). Primary brain injury leads to secondary events, including hypoxia, excitotoxicity, free radical generation, vascular dysfunction, apoptotic cell death, the inflammatory response and brain edema (Eakin et al., 2013; Chandran et al., 2018; Lu et al., 2019; Ng and Lee, 2019; Shi et al., 2019). As consequences of this damage, the concentrations of neurotransmitters, including monoamines (DA, norepinephrine, and serotonin) (Massucci et al., 2004; Bueno-Nava et al., 2008, 2010b; Huang et al., 2014a; Chen et al., 2015b, 2017b) and amino acids (GABA and glutamate) (Krobert et al., 1994; Bueno-Nava et al., 2008, 2010a; Shin et al., 2011; Guerriero et al., 2015), change in other brain structures. Glutamate release is associated with excitotoxicity following TBI, which leads to neuronal death (Guerriero et al., 2015), and elevated glutamate levels that persist over time (up to 4 days) are associated with a high mortality rate (23.6%) or with poor functional recovery in patients with injury (Chamoun et al., 2010).

Other consequences of brain injury are alterations in adjacent or distant neural groups with respect to the brain cortex, including structures that are anatomically related to the injured site, such as the striatum, cerebellum, pons, and hippocampus (Dunn-Meynell and Levin, 1997; Reep and Corwin, 1999; Van Vleet et al., 2003; Park et al., 2007; Bueno-Nava et al., 2008, 2010b; Doig et al., 2010; Kernie and Parent, 2010; Wiley et al., 2016; Shipp, 2017; Gálvez-Rosas et al., 2019). Therefore, brain injury results in disruption of the connectivity of the corticostriatal, corticohypothalamic, corticopontocerebellar, and cerebellothalamocortical pathways (Leergaard, 2003; Daskalakis et al., 2004; Shepherd, 2013). Other neural groups, such as the dopaminergic, noradrenergic, histaminergic and serotonergic systems, are altered by local axonal injury in brain contusions and direct mechanical injury (Bueno-Nava et al., 2008, 2010b; Eakin et al., 2013; Jenkins et al., 2016, 2018; Avila-Luna et al., 2019; Liao et al., 2019; Dougherty et al., 2020).

Striatal Dopaminergic Disruption After TBI

Primary cortical injury also involves local destruction of dopaminergic axons, a critical factor in the disruption of striatal dopaminergic signaling after TBI (Chen et al., 2017a; Karelina et al., 2017; Jenkins et al., 2018; Lu et al., 2019; Dougherty et al., 2020). As mentioned above, several events occur during secondary injury, but one event of interest in our review is the disruption of the nigrostriatal dopaminergic system at the striatal level (Figure 1B).

In the dorsal striatum, TBI is associated with effects on dopaminergic transmission on the side ipsilateral to the injury, such as reductions in the synthesis and release of striatal DA (Figure 1B; Wagner et al., 2005b; Shin et al., 2011; Van Bregt et al., 2012; Huang et al., 2014a; Chen et al., 2015b), subacute and chronic deficits in tyrosine hydroxylase activity (Wagner et al., 2005b; Hutson et al., 2011; Shin et al., 2011) and decreases in DAT levels in the striatum ipsilateral and/or contralateral to the injury (Donnemiller et al., 2000; Wagner et al., 2005a, b, 2014; Karelina et al., 2017). All previously mentioned studies indicate injury to dopaminergic neuronal cell bodies in the SNc (Jenkins et al., 2018). Patients with moderate-severe TBI reduced striatal DAT levels in the caudate nucleus (Figure 1B; Jenkins et al., 2018).

In striatonigral MSNs, D1R activation increases the phosphorylation of the cAMP-regulated protein of 32 kDa (DARPP-32) at Thr34 (p-DARPP-32-Thr34) (Langley et al., 1997; Greengard et al., 1999; Calabresi et al., 2000; Undieh, 2010; Rangel-Barajas et al., 2015). Bales et al. (2011) showed that TBI decreases p-DARPP-32-Thr34 levels on both sides of the striatum and that the decrease in Thr34 phosphorylation is due to increased activity of protein phosphatase-1 (PP-1). DARPP-32 is a phosphoprotein regulated by DA, and one explanation for the decrease in DARPP-32 phosphorylation at Thr34 is a decrease in DA signaling, while the increased activity of PP-1 is associated with an alteration in PKA (Bales et al., 2011). Molecular studies in our laboratory on rats that had recovered from motor deficits at 192 h after cortical injury showed that D1R mRNA expression was decreased in the striatum ipsilateral to the injury site. This reduction in D1R mRNA expression was reversed by systemic administration of the D1R agonist SKF-38393 (2 mg/kg), an effect that was blocked by the D1R antagonist SCH-23390 (Gálvez-Rosas et al., 2019). In another study, we evaluated the effect of SKF-38393 on spontaneous motor activity in normal rats and found that it increased both the distance traveled and horizontal counts (Figure 2; Avila-Luna et al., 2018b). This increased locomotion was prevented by coadministration of SCH-23390; however, administration of SCH-23390 alone decreased both the distance traveled and the horizontal counts (Figure 2; Avila-Luna et al., 2018b). In this same study, we showed that D1Rs mediated the SCH-23390-induced deficits in motor coordination and spontaneous motor activity and that the effect was reversed upon subsequent administration of the full D1R agonist SKF-82958 (Avila-Luna et al., 2018a, b). However, the use of a D1R agonist did not accelerate motor recovery, although an intact striatum may be necessary to achieve recovery at 192 h postinjury (Avila-Luna et al., 2018a). Few studies have investigated neuronal injury in the striatum in humans and animals after TBI (Primus et al., 1997; Huang et al., 2018); more information on this type of injury is needed to better interpret the changes in D1R expression and function that occur in the striatum after TBI.

FIGURE 2 Effects of systemic administration of SKF-38393 alone, coadministration of SKF-38393 + SCH-23390 and administration of SCH-23390 alone on horizontal movement (distance traveled) and vertical movement (rearing behavior) in the spontaneous motor activity test. Representative maps for the distance traveled in each treatment group obtained at 20 or 40 min after drug administration (A). Analysis of the groups (B). The values are reported as the means ± SEMs. The statistical analyses were performed using one-way ANOVA followed by Dunnett’s test. +P < 0.05 and ++P < 0.02 compared with the vehicle group. The results shown have been reported previously (Avila-Luna et al., 2018b).

Another subpopulation of striatopallidal MSNs expresses D2-like receptors (D2Rs), which were recently reported to be altered in humans after TBI (Jolly et al., 2019) and have been studied and verified in animal models (Karelina et al., 2017). Immunohistochemistry of mouse tissues has indicated that D2R expression is decreased in the striatum ipsilateral to the injury site (Karelina et al., 2017), but such a decrease can be reversed by exercise on a motorized treadmill in rats that are exercised after injury, as reported by Ko et al. (2019). Two binding studies using single-photon or positron emission tomography (PET) have shown that striatal D2R binding is reduced in human patients with TBI (Donnemiller et al., 2000; Jolly et al., 2019). Another study has shown that caudate and putamen binding is reduced in patients with TBI and a length polymorphism near the D2R gene (Wagner et al., 2014). Low binding may be associated with nigrostriatal fiber loss (Donnemiller et al., 2000; Wagner et al., 2014).

The abovementioned evidence suggests that the dopaminergic system in the striatum is altered after TBI and that functional recovery is modulated by a D1R-dependent mechanism (Davis et al., 2007). Nevertheless, further studies on the striatum are needed to determine D2R function after TBI.

Mechanisms of Action of Dopaminergic Drugs and Their Beneficial Effects on Brain Injury

Due to the high levels of D1R and D2R expression in the striatum and the strong connectivity of cortical glutamatergic afferents with both MSNs and dopaminergic afferents, alterations in this neuronal population may contribute to selective neuronal dysfunction and degeneration after brain injury (Jackson and Westlind-Danielsson, 1994; Le Moine and Bloch, 1995; Surmeier et al., 1996, 2007; Gerfen and Surmeier, 2011; Guerriero et al., 2015). Previous studies have shown that drugs that modulate dopaminergic transmission elicit favorable results during rehabilitation of patients with TBI, such as enhanced cognitive recovery, executive function, attentional function, processing speed and memory (Figure 1C; Harmon and Boyeson, 1997; Bales et al., 2009; Frenette et al., 2011, 2012; Osier and Dixon, 2016a; Plummer et al., 2018). Dopaminergic drugs administered to patients with TBI have various mechanisms of action, such as blockade of DAT, inhibition of DA reuptake and facilitation of DA synthesis. MPD, amantadine and bromocriptine are among the drugs most highly recommended by the Neurotrauma Foundation (Bales et al., 2009).

Effects on DA Reuptake and the DAT

Catecholamine levels in the brain are increased in the first few hours after brain injury but decrease thereafter (Huger and Patrick, 1979; Dunn-Meynell et al., 1994; Levin et al., 1995; Osier and Dixon, 2016a). Striatal DA levels are altered in this way (Chen et al., 2015b, 2017b), and the alterations are accompanied by decreases in local and striatal DAT expression from the first to fourth weeks after cortical injury (Wagner et al., 2005a, b). The dorsal striatum is innervated by dopaminergic afferents from the SNc, which form synaptic contacts with dendritic spine necks on MSNs (Freund et al., 1984), and DAT is localized in the cell membrane of dopaminergic axons and terminals (Hersch et al., 1997). Focal cortical injury leads to loss of MSN spines and to decreases in synaptic contacts (Kemp et al., 1971; Cheng et al., 1997; Neely et al., 2007). In this context, imaging results in humans (Donnemiller et al., 2000) have been consistent with western blot findings (Wagner et al., 2005a, b), indicating that striatal DAT levels are decreased after brain injury (Wagner et al., 2005b). However, DAT inhibitors including amphetamine (Feeney et al., 1982; Hovda et al., 1987; Rau et al., 2016; Duong et al., 2018), MPD (Kline et al., 1994, Kaelin et al., 1996, Kline et al., 2000; Arciniegas et al., 2002; Weber and Lütschg, 2002; Demarchi et al., 2005; Wagner et al., 2007; Wortzel and Arciniegas, 2012; Ekinci et al., 2017), and amantadine (Arciniegas et al., 2002; Demarchi et al., 2005; Wu and Garmel, 2005; Wortzel and Arciniegas, 2012; Bleimeister et al., 2019; Okigbo et al., 2019; Loggini et al., 2020) have been used in animals and humans to evaluate the neuroprotective and symptomatic effects associated with improved recovery after brain injury. MPD and amantadine are clinically relevant treatments for TBI during the acute and chronic phases, including during the rehabilitative period (Arciniegas et al., 2002; Demarchi et al., 2005; Warden et al., 2006; Bales et al., 2009). In patients with TBI, administration of these drugs ameliorates neurocognitive impairments in attention, memory and executive function (Arciniegas et al., 2002; Rau et al., 2016). One explanation for the clinical use of DAT inhibitors despite the abnormally low DAT levels, is associated with changes in catecholamines after TBI (Osier and Dixon, 2016a), particularly decreases in catecholamine levels (Levin et al., 1995; Chen et al., 2015a, 2017b; Osier and Dixon, 2016a).

DA Synthesis and Release

Functional neuroimaging results have shown that the substantia nigra is altered after cortical injury in TBI patients (Jenkins et al., 2018; Lu et al., 2019) and that this alteration can promote progressive degeneration of nigrostriatal dopaminergic neurons (Figure 1B; Hutson et al., 2011; Van Bregt et al., 2012). Subsequently, it leads to alterations in dopaminergic signaling in the striatum, including reductions in the synthesis and release of striatal DA (Wagner et al., 2005b; Shin et al., 2011; Van Bregt et al., 2012; Huang et al., 2014a; Chen et al., 2015b) and subacute and chronic deficits in tyrosine hydroxylase activity (Wagner et al., 2005b; Hutson et al., 2011; Shin et al., 2011). Levodopa is a DA precursor drug that is not only used to treat Parkinson’s disease but also administered to patients with stroke, as it exerts beneficial effects on motor recovery and cognitive function (Liepert, 2008; Seniów et al., 2009). In patients with TBI, levodopa is used to treat cognitive impairment (Arciniegas et al., 2002) and altered-consciousness states (Krimchansky et al., 2004; Matsuda et al., 2005). Clinical studies administering levodopa alone have been scarce and have included a limited number of patients (Demarchi et al., 2005); however, in some of these studies, administration of levodopa has improved the cognitive function and behaviors of all patients (Lal et al., 1988). Other studies have reported some beneficial effects of levodopa in clinical cases (Demarchi et al., 2005). For example, levodopa can be combined with other drugs, such as pramipexole, ropinirole, amantadine and bromocriptine, to improve apraxia (Jang et al., 2018; Choi et al., 2020). To exert its effects, levodopa increases striatal DA levels, which can lead to changes in signaling at DA receptors, including both D1Rs and D2Rs (De La Fuente-Fernandez et al., 2004; Aubert et al., 2005; Guigoni et al., 2005).

D2Rs are localized on dopaminergic axons (Bjorklund and Dunnett, 2007), in striatopallidal MSNs, in cholinergic interneurons and on corticostriatal terminals in the striatum (Le Moine and Bloch, 1995; Kreitzer and Malenka, 2008; Valjent et al., 2009). Bromocriptine is an ergot alkaloid and D2R-selective agonist that is known to enhance cognitive function in the chronic recovery period after brain injury (Ozga et al., 2018). In the traditional mechanism, DA D2 autoreceptor activation by agonist drugs at striatal presynaptic sites inhibits DA release (Brannan et al., 1993; L’hirondel et al., 1998; Schmitz et al., 2002, 2003) and synthesis (Schmitz et al., 2003; Yoshida et al., 2006). However, postsynaptic D2R activation modulates the functions of GABAergic MSNs and interneurons (Surmeier et al., 2007; Keeler et al., 2014). Notably, low (2.5 mg/kg) and medium (5 mg/kg) doses of bromocriptine increase DA release, an effect associated with the action of bromocriptine as a partial antagonist (Brannan et al., 1993). Compared with healthy control patients, who exhibit improved working memory, patients with mild TBI have altered responsivity to DA after administration of 1.25 mg of bromocriptine at 1 month after brain injury (Mcallister et al., 2011). In one study, administration of doses of 1.25 or 2.5 mg of bromocriptine 2 times daily resulted in enhanced functional recovery in patients with TBI who were in a vegetative state; however, the authors recognized the small sample size analyzed as a limitation of the study (Passler and Riggs, 2001). As mentioned above, bromocriptine is a D2R agonist but may also act as a partial antagonist (Lieberman and Goldstein, 1985), and some studies have shown a protective effect of bromocriptine against oxidative stress (Kline et al., 2004; Bales et al., 2009; Osier and Dixon, 2016a).

Dopaminergic Mechanism of Action in Functional Recovery After Brain Injury

The mechanisms of action of the dopaminergic drugs used to treat TBI have not been completely clarified, primarily because dopaminergic receptor activation may lead to restoration of neuronal circuits after injury in brain structures with high densities of these receptors. Dopaminergic abnormalities following TBI are clearly associated with functional disability in animals and humans (Bales et al., 2009; Osier and Dixon, 2016a, b; Jenkins et al., 2018; Traeger et al., 2020; Tsuda et al., 2020), and drugs with dopaminergic actions are beneficial for functional recovery after brain injury (Meythaler et al., 2002; Matsuda et al., 2005; Frenette et al., 2012; Huang et al., 2014b; Duong et al., 2018; Lan et al., 2019; Okigbo et al., 2019; Loggini et al., 2020). In the striatum, activation of D1Rs and D2Rs on MSNs is associated with increased and decreased excitability, respectively, in response to corticostriatal glutamatergic inputs (Wickens and Wilson, 1998; Surmeier et al., 2007; Gerfen and Surmeier, 2011). The classic model of basal ganglia function (Figure 1A) suggests that glutamatergic corticostriatal projections are critical for the activity of striatonigral and striatopallidal MSNs that form the direct and indirect pathways in the basal ganglia, respectively (Albin et al., 1989). Alterations in dopaminergic function in the striatum are associated with motor disability, such as that observed in individuals with Parkinson’s disease and levodopa-induced dyskinesia (Calabresi et al., 2014; Bastide et al., 2015; Fundament et al., 2016; Schonfeld et al., 2017; Avila-Luna et al., 2019). Therefore, some components of TBI pathophysiology likely have a basis in striatal dopaminergic dysfunction based on clinical and experimental evidence obtained from the basal ganglia, particularly the dorsal striatum (Figure 1B; Donnemiller et al., 2000; Costa et al., 2006; Yan et al., 2007; Bales et al., 2009, 2011; Van Bregt et al., 2012; Osier and Dixon, 2016a; Karelina et al., 2017; Treble-Barna et al., 2017; Jenkins et al., 2018; Jolly et al., 2019). Similar to Parkinson’s disease, TBI leads to a hypodopaminergic state in the long term (Wagner et al., 2014; Jenkins et al., 2016; Karelina et al., 2017; Fridman et al., 2019). Various drugs have been used to counteract the adverse effects of the hypodopaminergic state, including DA agonists such as bromocriptine and amantadine, dopaminergic drugs used for Parkinson’s disease; stimulants; and reuptake inhibitors (Figure 1C and Table 1; Osier and Dixon, 2016a; Fridman et al., 2019).

TABLE 1 Main clinical effects of dopaminergic drugs on traumatic brain injury.

Drug	Mechanism of action	Clinical effects on traumatic brain injury	Side effects and limitations	References	
Amantadine	Increases dopamine release and inhibits dopamine reuptake. Weak non-competitive NMDA receptor antagonist.	Post-concussion syndrome: decreases headache; exerts mild effects on memory, dizziness and behavioral disturbances.	Nausea, dizziness, insomnia, renal toxicity and decreased threshold for seizures.	Reddy et al., 2013; Carabenciov et al., 2019; Ma and Zafonte, 2020	
		Behavioral symptoms: aggressiveness, agitation, apathy and irritability.		Gramish et al., 2017; Hammond et al., 2017; Ter Mors et al., 2019	
		Ameliorates cognitive disturbances.		Ghate et al., 2018; Loggini et al., 2020	
		Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state.		Giacino et al., 2012; Hadgu et al., 2020	
		Stimulates of neuroplasticity processes in the acute stage.		Spritzer et al., 2015	
Modafinil	Increases the levels of dopamine, norepinephrine, histamine, serotonin, and orexins.	Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state.	Nervousness, headache, dizziness, insomnia, nausea, rhinitis.	Dhamapurkar et al., 2017; Borghol et al., 2018; Repantis et al., 2021	
		Ameliorates posttraumatic excessive daytime sleepiness.		Kaiser et al., 2010	
Methylphenidate	Increases the release of dopamine and inhibits its reuptake.	Cognitive disorders: improves attention, mental fatigue, working memory, executive functions, and processing speed.	Headache, insomnia, hyporexia, nausea, anxious feelings, increased heart rate and blood pressure.	Johansson et al., 2015, 2017; Manktelow et al., 2017; Zhang and Wang, 2017; Dorer et al., 2018; Espadas et al., 2018; Chien et al., 2019; Al-Adawi et al., 2020; Barnett and Reid, 2020	
Bromocriptine	D2R agonist.	Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state.	Hypotension, nausea, vomiting, confusion, constipation, dizziness.	Celik et al., 2015; Munakomi et al., 2017; Otero Villaverde et al., 2019	
		Ameliorates cognitive disturbances.		Munakomi et al., 2017	
		Ameliorates central hyperthermia.		Zakhary and Sabry, 2017	
Apomorphine	Non-selective D2R and D1R receptor agonist.	Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state.	Nausea, vomiting, headache, abnormal movements, hallucinations.	Fridman et al., 2010; Auffret et al., 2019	
Rotigotine	Non-selective D1R to D5R agonist with the highest affinity for D3R.	Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state.	Changes in blood pressure, drowsiness, hallucinations, fainting, fluid retention.	Lan et al., 2019; Corsi et al., 2020	
Pergolide	Non-selective D2R and D1R agonist.	Cognitive disturbances: improves working memory.	Dyskinesia, hallucinations, disturbance of sleep, loss of appetite, nausea, hypotension, tachycardia.	Flashman et al., 2021	
Levodopa	Dopamine precursor.	Stimulates alertness in patients with altered states of consciousness such as unresponsive wakefulness syndrome or a minimally conscious state. Used as an adjuvant therapy for motor recovery.	Dyskinesia, nausea, vomiting, hypotension, mania, hallucinations.	Matsuda et al., 2005; Ennis et al., 2013; Bradley and Damiano, 2019	

Functional Interactions Between DA and Other Neurotransmission Systems in the Striatum

In the striatum, MSN heteroreceptors are localized in the cell membrane, including DA receptors (D1Rs and D2Rs), histamine receptors (H3Rs), muscarinic receptors (M1 and M4), adenosine receptors (A1Rs and A2ARs), cannabinoid receptors (CB1Rs), metabotropic glutamate receptors (mGlu1/5Rs), and ionotropic glutamate receptors [N-methyl-D-aspartic acid (NMDA) receptors, NMDARs] (Jones et al., 2001; Meschler and Howlett, 2001; Kreitzer and Malenka, 2008; Bolam and Ellender, 2016; Rapanelli, 2017). As mentioned above with regard to the role of DA after TBI and during functional recovery, studies have shown that functional interactions exist between DA receptors and other heteroreceptors localized in MSNs of the striatum, such as D1R/A1R (Fuxe et al., 2008, 2010), D1R/D3R/A1R (Fuxe et al., 2008), D1R/D3R (Fuxe et al., 2008; Marcellino et al., 2008), D1R/H3R (Garcia et al., 1997; Ferrada et al., 2009; Moreno et al., 2011; Avila-Luna et al., 2019), D2R/A2AR (Fuxe et al., 2008, 2010; Ferré et al., 2016; Ferré and Ciruela, 2019), D2R/H3R (Humbert-Claude et al., 2007; Ferrada et al., 2008; Rapanelli et al., 2016; Rapanelli, 2017), D2R/A2AR/mGlu5R (Fuxe et al., 2008, 2010), D2R/NMDA (Fuxe et al., 2008), D2R/CB1R (Fuxe et al., 2008), and D2R/CB1R/A2AR (Meschler and Howlett, 2001; Fuxe et al., 2008, 2010) interactions (see Figure 3). Most of these functional interactions regulate neuronal activity via the adenylyl cyclase-mediated response in MSNs from both direct and indirect pathways of the basal ganglia (see Figure 3), but other interactions, such as D2R/NMDAR interactions, are associated with modulation of transmembrane ion currents (Fuxe et al., 2008). One explanation for the relevance of functional interactions between receptors to TBI-mediated effects involves the D1R/H3R functional interaction in MSNs, as it has been reported that H3R activation by the agonist immepip selectively inhibits the component of depolarization-evoked GABA release that depends on concomitant D1R stimulation in rat striatum and substantia nigra pars reticulata (SNr) slices (Garcia et al., 1997; Arias-Montaño et al., 2001). At the postsynaptic level, H3R activation inhibits D1R-induced cAMP formation in rat striatal slices (Sanchez-Lemus and Arias-Montano, 2004), and D1Rs play a permissive role in H3R-mediated activation of mitogen-activated protein kinases (MAPKs) (Moreno et al., 2011). At the motor behavior level, chronic H3R activation reduces dyskinesias induced by L-Dopa (L-3,4-dihydroxyphenylalanine) in rats with 6-hydroxydopamine-induced lesions (Avila-Luna et al., 2019). All of the functional interactions mentioned above may have important implications for future research on TBI and its treatment.

FIGURE 3 Schematic representation of functional interactions between DA receptors and other heteroreceptors localized in medium spiny neurons (MSNs). Red indicates excitatory projections, and black indicates inhibitory projections. In the striatum, GABAergic MSNs communicate with neurons in the substantia nigra pars reticulata (SNr) or internal segment of the globus pallidus (GPi) through a direct pathway and to the external segment of the globus pallidus (GPe); the GPe in turn projects to the subthalamic nucleus (STN), which projects to the SNr, forming the indirect pathway. The orange color represents the substantia nigra pars compacta (SNc). D1R, D1 receptor; D2R, D2 receptor; A1R, A1 receptor; A2R, A2 receptor; H3R, H3 receptor; D3R, D3 receptor; mGlu5R, mGlu5 receptor; CB1R, CB1 receptor; PKA, protein kinase A.

Clinical Functional Recovery Associated With the Dopaminergic System

By ∼10 or ∼20 years after injury, most patients with moderate and severe TBI show good recovery or moderate disability (Andelic et al., 2018). Facilitation or modulation of functional recovery is an important goal of rehabilitation in all patients with severe TBI, but the degree of recovery varies among patients due to factors associated with the injury and to the patients’ biological and physical characteristics. One common limitation in the published studies is a small sample size. In this context, we considered illustrative examples from studies included in this review that provide evidence for an association between functional recovery and the dopaminergic system.

Pharmacological and physical rehabilitation is commonly utilized to treat patients with TBI (Horn et al., 2015; Bhatnagar et al., 2016; Ng and Lee, 2019; Traeger et al., 2020). As mentioned previously, dopaminergic drugs are often administered after brain injury. The evidence for an association of the dopaminergic system with functional recovery is described below. In the dopaminergic system, the nigrostriatal pathway is implicated in spatial learning/memory, reward processing and cognitive function, whereas the mesocorticolimbic pathway is associated with memory consolidation, motivation and addiction (Osier and Dixon, 2016a). A review by Osier and Dixon has suggested that therapies targeting the catecholaminergic system may attenuate functional limitations after moderate and severe TBI (Osier and Dixon, 2016a) and functional disability that may persist even decades after brain injury (Andelic et al., 2018).

Evidence indicates that DA neurotransmission is disrupted following moderate and severe TBI, and benefits associated with dopaminergic system-affecting drugs have been reported (Passler and Riggs, 2001; Meythaler et al., 2002; Sawyer et al., 2008; Bales et al., 2009; Jenkins et al., 2016, 2018; Osier and Dixon, 2016a; Lan et al., 2019). For example, administration of amantadine at 100–200 mg (twice a day) to patients with TBI appears to be beneficial in promoting intermediate-term cognitive recovery (Loggini et al., 2020). Administration of methamphetamine, which is highly addictive and is of limited usefulness due to its potential for abuse and dependence, to patients with TBI improves Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) scores, whereas in injured rats, it improves motor and cognitive performance in a dose-dependent manner (Duong et al., 2018). Bromocriptine enhances arousal in patients with TBI who are in a minimally conscious state and improves neurological sequelae associated with hemiparesis (56% of cases), aphasia (80%), memory (50%), and cognitive impairment (67%) (Munakomi et al., 2017). Administration of MPD at a dose of 0.3 mg/kg (∼2.5 mg) exerts positive effects on attention deficits after TBI (Whyte et al., 2004).

Clinical Evidence Associated With the Dopaminergic System

Clinically, a variety of drugs with dopaminergic effects are used for TBI. These drugs have diverse dosing and application regimens and clinical indications. A prudent approach would be to first describe two main categories of drugs that differ on the basis of their clinical use. The first category includes drugs that are used as adjuvant stimulant treatments during the rehabilitation or recovery period in patients with TBI. The expected (at least theoretically) effects of these drugs in modulating neuroplasticity processes are cumulative and long-term; such effects result in improved functional recovery of patients during follow-up (Ghalaenovi et al., 2018). The second category includes drugs that are administered to treat any symptoms or complications that patients are currently experiencing, for example, behavioral disturbances (aggressiveness and irritability), mood or motivational disorders (depression, apathy, etc.) and cognitive complaints (attention, posttraumatic amnesia, etc.) (Ter Mors et al., 2019).

The drugs that have been most commonly used in the clinic include amantadine, levodopa, amphetamine, MPD, bromocriptine and pergolide, among others. These drugs differ widely in their pharmacokinetic properties, mechanisms of action and selectivity for the dopaminergic system (Table 1; Lan et al., 2019). On the other hand, drugs with dopaminergic action have been used to treat various clinical conditions; for example, stimulants have been used in patients with disorders of consciousness, including patients with unresponsive wakefulness syndrome and patients in a minimally conscious state (Gao et al., 2020); for the treatment of some cognitive complaints such as attention disorders, posttraumatic amnesia, and executive or working memory dysfunction (Whyte et al., 2008); for management of behavior or mood alterations, such as aggressiveness, apathy, and agitation (Hammond et al., 2017); for stimulation of motor recovery; and even for management of autonomic dysfunctions secondary to TBI (Ghalaenovi et al., 2018). These drugs have mainly been administered to patients with severe TBI sequelae; however, reports have also described their use in patients with mild TBI (Iaccarino et al., 2020). The evolution of the injury is also highly variable, namely, the evolution from the acute or subacute stage to the chronic stage, which undoubtedly influences the clinical results obtained (Hammond et al., 2017). Additionally, the duration of treatment and the doses used have varied widely among different studies. For some drugs, such as amantadine, systematic reviews or meta-analyses have been published because numerous studies are available (Loggini et al., 2020); in contrast, for other drugs, only anecdotal reports of their use in case reports or case series are available. Finally, although multiple studies have shown positive effects of dopaminergic drugs, studies have also reported negative results; thus, the evidence is not entirely consistent in this regard (Hammond et al., 2017). A detailed description of each of the dopaminergic drugs and their clinical effects on TBI is beyond the scope of this review, but some recent publications on this topic are available (Carrillo-Mora et al., 2017; Bradley and Damiano, 2019). This variability among studies increases the difficulty of reaching categorical conclusions on the usefulness of dopaminergic drugs for TBI treatment in the clinical setting; however, the currently available evidence appears to suggest that they improve some disorders in patients with TBI, such as attention and alertness disorders, aggressiveness, and other behavioral symptoms. However, more clinical studies are needed to provide stronger support for their positive effects.

It is very important to emphasize that in the clinical management of TBI patients, in addition to using dopamine agonists for different purposes, clinicians frequently use dopamine antagonists (antipsychotics; either typical or atypical, which have different selectivities for D1Rs and D2Rs) to control some acute symptoms/complications, such as agitation, delirium, hallucinations and psychosis (Polich et al., 2019; Williamson et al., 2019). However, also importantly, there is experimental and clinical evidence that some of these dopaminergic blockers may have negative effects on neuroplasticity processes, affecting motor or cognitive recovery in patients with brain damage (Phelps et al., 2015; Folweiler et al., 2017). In this sense, previous studies have suggested that atypical antipsychotics have better safety profiles than typical antipsychotics (Phelps et al., 2017). Interestingly, this evidence regarding the negative effects of dopamine antagonists on motor or cognitive recovery from brain damage also indirectly supports the hypothesis that dopamine stimulation is a good therapeutic strategy for stimulation of motor and cognitive recovery after TBI; however, more studies are needed to confirm or rule out these negative effects of antipsychotic drugs.

Conclusion

Facilitation or modulation of functional recovery is an important goal of rehabilitation in all patients after severe TBI, but the degree of recovery varies among patients due to factors associated with the biological and physical characteristics of the patients, the variety of the drugs and of the dosing and application regimens used, and clinical indications. A limitation of most studies is a small sample size. In this context, we considered illustrative examples from studies that were included in this review and provided some evidence for functional recovery associated with the dopaminergic system. Importantly, the dopaminergic nigrostriatal pathway is implicated in spatial learning/memory, reward processing, cognitive function and motor function, whereas the mesocorticolimbic pathway is associated with memory consolidation, motivation and addiction. In this review, we have described experimental and clinical evidence indicating that DA neurotransmission is disrupted following TBI and discussed the benefits associated with administration of dopaminergic system-affecting drugs. Ultimately, our review shows that TBI-induced disability may be partially associated with alterations in nigrostriatal dopaminergic signaling in the striatum that are localized in the basal ganglia and establish reciprocal interconnections with the corticostriatal pathway.

Author Contributions

AB-N, AV-M, PC-M, and AA-L: drafting and refining of the manuscript. DM-R, AG-R, and AO-H: critical reading of the manuscript. All authors: read and approved the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. This work was supported by INR-LGII (research project numbers: 91/17 and 06/18) and CONACyT (grants: CB-2016-287614 to AB-N and CB-2016-288512 to AA-L).
==== Refs
References

Abekawa T. Ohmori T. Ito K. Koyama T. (2000). D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res. 867 250–254. 10.1016/s0006-8993(00)02298-8 10837822
Al-Adawi S. Al-Naamani A. Jaju S. Al-Farsi Y. M. Dorvlo A. S. S. Al-Maashani A. (2020). Methylphenidate improves executive functions in patients with traumatic brain injuries: a feasibility trial via the idiographic approach. BMC Neurol. 20 :103 .
Albin R. L. Young A. B. Penney J. B. (1989). The functional-anatomy of basal ganglia disorders. Trends Neurosci. 12 366–375.2479133
Andelic N. Howe E. I. Hellstrom T. Sanchez M. F. Lu J. Lovstad M. (2018). Disability and quality of life 20 years after traumatic brain injury. Brain Behav. 2018 :8 .
Arciniegas D. B. Held K. Wagner P. (2002). Cognitive impairment following traumatic brain injury. Curr. Treat. Option. Neurol. 4 43–57.
Arias-Montaño J. A. Floran B. Garcia M. Aceves J. Young J. M. (2001). Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of (3)H-gamma-aminobutryic acid from rat striatal slices. Br. J. Pharm. 133 165–171. 10.1038/sj.bjp.0704053 11325806
Assous M. Dautan D. Tepper J. M. Mena-Segovia J. (2019). Pedunculopontine glutamatergic neurons provide a novel source of feedforward inhibition in the striatum by selectively targeting interneurons. J. Neurosci. 39 4727 . 10.1523/jneurosci.2913-18.2019 30952811
Aubert I. Guigoni C. Hakansson K. Li Q. Dovero S. Barthe N. (2005). Increased D-1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 17–26. 10.1002/ana.20296 15514976
Auffret M. Drapier S. Vérin M. (2019). New tricks for an old dog: A repurposing approach of apomorphine. Eur. J. Pharmacol. 843 66–79. 10.1016/j.ejphar.2018.10.052 30395851
Avila-Luna A. Galvez-Rosas A. Alfaro-Rodriguez A. Reyes-Legorreta C. Garza-Montano P. Gonzalez-Pina R. (2018a). Dopamine D1 receptor activation maintains motor coordination in injured rats but does not accelerate the recovery of the motor coordination deficit. Behav. Brain Res. 336 145–150. 10.1016/j.bbr.2017.08.026 28842271
Avila-Luna A. Galvez-Rosas A. Durand-Rivera A. Ramos-Languren L. E. Rios C. Arias-Montano J. A. (2018b). Dopamine D1 receptor activation maintains motor coordination and balance in rats. Metab. Brain Dis. 33 99–105. 10.1007/s11011-017-0126-x 29052075
Avila-Luna A. Ríos C. Gálvez-Rosas A. Montes S. Arias-Montano J.-A. Bueno-Nava A. (2019). Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats. Psychopharmacology 236 1937–1948. 10.1007/s00213-019-5182-y 30762089
Bales J. W. Wagner A. K. Kline A. E. Dixon C. E. (2009). Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. Neurosci. Biobehav. Rev. 33 981–1003. 10.1016/j.neubiorev.2009.03.011 19580914
Bales J. W. Yan H. Q. Ma X. Li Y. Samarasinghe R. Dixon C. E. (2011). The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: A novel therapeutic target in traumatic brain injury. Exp. Neurol. 229 300–307. 10.1016/j.expneurol.2011.02.013 21376040
Barnett M. Reid L. (2020). The effectiveness of methylphenidate in improving cognition after brain injury in adults: a systematic review. Brain Injury 34 1–10. 10.1080/02699052.2019.1667538 31526025
Bastide M. F. Meissner W. G. Picconi B. Fasano S. Fernagut P. O. Feyder M. (2015). Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog. Neurobiol. 132 96–168.26209473
Bergson C. Mrzljak L. Smiley J. F. Pappy M. Levenson R. Goldman-Rakic P. S. (1995). Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J. Neurosci. 15 7821–7836. 10.1523/jneurosci.15-12-07821.1995 8613722
Bhatnagar S. Iaccarino M. A. Zafonte R. (2016). Pharmacotherapy in rehabilitation of post-acute traumatic brain injury. Brain Res. 1640 164–179. 10.1016/j.brainres.2016.01.021 26801831
Bjorklund A. Dunnett S. B. (2007). Dopamine neuron systems in the brain: an update. Trends Neurosci. 30 194–202. 10.1016/j.tins.2007.03.006 17408759
Bleimeister I. H. Wolff M. Lam T. R. Brooks D. M. Patel R. Cheng J. P. (2019). Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury. Brain Res. 1714 227–233. 10.1016/j.brainres.2019.03.007 30876859
Bolam J. P. Ellender T. J. (2016). Histamine and the striatum. Neuropharmacology 106 74–84. 10.1016/j.neuropharm.2015.08.013 26275849
Bolam J. P. Hanley J. J. Booth P. A. Bevan M. D. (2000). Synaptic organisation of the basal ganglia. J. Anat. 196 (Pt 4 ), 527–542. 10.1046/j.1469-7580.2000.19640527.x 10923985
Borghol A. Aucoin M. Onor I. Jamero D. Hawawini F. (2018). Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury. Innov. Clin. Neurosci. 15 17–23.
Bostan A. C. Strick P. L. (2010). The Cerebellum and Basal Ganglia are Interconnected. Neuropsychol. Rev. 20 261–270. 10.1007/s11065-010-9143-9 20811947
Bradley C. L. Damiano D. L. (2019). Effects of Dopamine on Motor Recovery and Training in Adults and Children With Nonprogressive Neurological Injuries: A Systematic Review. Neurorehabilit. Neural. Repair 33 331–344. 10.1177/1545968319837289 30913975
Brannan T. Martínez-Tica J. Di Rocco A. Yahr M. D. (1993). Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study. J. Neural. Transm. Park Dis. Dement Sect. 6 81–87. 10.1007/bf02261001 7509606
Bueno-Nava A. Gonzalez-Pina R. Alfaro-Rodriguez A. (2010a). Iron-dextran injection into the substantia nigra in rats decreases striatal dopamine content ipsilateral to the injury site and impairs motor function. Metab. Brain Dis. 25 235–239. 10.1007/s11011-010-9200-3 20424901
Bueno-Nava A. Gonzalez-Pina R. Alfaro-Rodriguez A. Nekrassov-Protasova V. Durand-Rivera A. Montes S. (2010b). Recovery of Motor Deficit, Cerebellar Serotonin and Lipid Peroxidation Levels in the Cortex of Injured Rats. Neurochem. Res. 35 1538–1545. 10.1007/s11064-010-0213-4 20535555
Bueno-Nava A. Montes S. Delagarza-Montano P. Alfaro-Rodriguez A. Ortiz A. Gonzalez-Pina R. (2008). Reversal of noradrenergic depletion and lipid peroxidation in the pons after brain injury correlates with motor function recovery in rats. Neurosci. Lett. 443 32–36. 10.1016/j.neulet.2008.07.046 18662743
Bunzow J. R. Van Tol H. H. Grandy D. K. Albert P. Salon J. Christie M. (1988). Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336 783–787. 10.1038/336783a0 2974511
Calabresi P. Gubellini P. Centonze D. Picconi B. Bernardi G. Chergui K. (2000). Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity. J. Neurosci. 20 :8443 . 10.1523/jneurosci.20-22-08443.2000 11069952
Calabresi P. Picconi B. Tozzi A. Ghiglieri V. Di Filippo M. (2014). Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat. Neurosci. 17 1022–1030. 10.1038/nn.3743 25065439
Camps M. Kelly P. H. Palacios J. M. (1990). Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. J. Neural Trans. Gen. Sect. 80 105–127. 10.1007/bf01257077 2138461
Carabenciov I. D. Bureau B. L. Cutrer M. Savica R. (2019). Amantadine Use for Postconcussion Syndrome. Mayo Clin. Proc. 94 275–277. 10.1016/j.mayocp.2018.10.021 30711125
Carrillo-Mora P. Alcantar-Shramm J. M. Almaguer-Benavides K. M. Macías-Gallardo J. J. Fuentes-Bello A. Rodríguez-Barragán M. A. (2017). Pharmacological Stimulation of Neuronal Plasticity in Acquired Brain Injury. Clin. Neuropharmacol. 40 131–139. 10.1097/wnf.0000000000000217 28471767
Celik J. B. Duman A. Arun O. Onal I. O. Ilban O. Sonmez A. E. (2015). Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury. Intens. Care Med. Exp. 3 :A485 .
Chamoun R. Suki D. Gopinath S. P. Goodman J. C. Robertson C. (2010). Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J. Neurosurg. 113 564–570. 10.3171/2009.12.jns09689 20113156
Chandran R. Kim T. Mehta S. L. Udho E. Chanana V. Cengiz P. (2018). A combination antioxidant therapy to inhibit NOX2 and activate Nrf2 decreases secondary brain damage and improves functional recovery after traumatic brain injury. J. Cereb. Blood Flow Metab. 38 1818–1827. 10.1177/0271678x17738701 29083257
Chen Y.-H. Huang E. Y.-K. Kuo T.-T. Miller J. Chiang Y.-H. Hoffer B. J. (2017a). Impact of Traumatic Brain Injury on Dopaminergic Transmission. Cell Transplant. 26 1156–1168. 10.1177/0963689717714105 28933212
Chen Y. H. Huang E. Y. Kuo T. T. Ma H. I. Hoffer B. J. Tsui P. F. (2015a). Dopamine Release Impairment in Striatum After Different Levels of Cerebral Cortical Fluid Percussion Injury. Cell Transplant. 24 2113–2128. 10.3727/096368914x683584 25198499
Chen Y. H. Huang E. Y. K. Kuo T. T. Hoffer B. J. Miller J. Chou Y. C. (2017b). Dopamine release in the nucleus accumbens is altered following traumatic brain injury. Neuroscience 348 180–190. 10.1016/j.neuroscience.2017.02.001 28196657
Chen Y. H. Huang E. Y. K. Kuo T. T. Ma H. I. Hoffer B. J. Tsui P. F. (2015b). Dopamine Release Impairment in Striatum After Different Levels of Cerebral Cortical Fluid Percussion Injury. Cell Transplant. 24 2113–2128. 10.3727/096368914x683584 25198499
Cheng H.-W. Rafols J. A. Goshgarian H. G. Anavi Y. Tong J. Mcneill T. H. (1997). Differential Spine Loss and Regrowth of Striatal Neurons Following Multiple Forms of Deafferentation: A Golgi Study. Exp. Neurol. 147 287–298. 10.1006/exnr.1997.6618 9344554
Chien Y.-J. Chien Y.-C. Liu C.-T. Wu H.-C. Chang C.-Y. Wu M.-Y. (2019). Effects of Methylphenidate on Cognitive Function in Adults with Traumatic Brain Injury: A Meta-Analysis. Brain Sci. 9 :291 . 10.3390/brainsci9110291 31653039
Choi E. B. Kim J. Y. Jang S. H. (2020). Motor recovery of hemiparetic leg by improvement of limb-kinetic apraxia in a chronic patient with traumatic brain injury: A case report. Medicine 2020 :99 .
Corrigan J. D. Selassie A. W. Orman J. A. (2010). The Epidemiology of Traumatic Brain Injury. J. Head Trauma Rehabilit. 25 72–80.
Corsi F. M. Gerace C. Ricci M. (2020). Rotigotine effect in prolonged disturbance of consciousness. Brief Report of two cases. Acta Biomed. 91 132–133.32191667
Costa R. M. Lin S.-C. Sotnikova T. D. Cyr M. Gainetdinov R. R. Caron M. G. (2006). Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52 359–369. 10.1016/j.neuron.2006.07.030 17046697
Daskalakis Z. J. Paradiso G. O. Christensen B. K. Fitzgerald P. B. Gunraj C. Chen R. (2004). Exploring the connectivity between the cerebellum and motor cortex in humans. J. Physiol. 557 689–700. 10.1113/jphysiol.2003.059808 15047772
Davis E. J. H. Coyne C. Mcneill T. H. (2007). Intrastriatal dopamine D1 antagonism dampens neural plasticity in response to motor cortex lesion. Neuroscience 146 784–791. 10.1016/j.neuroscience.2007.01.039 17331653
De La Fuente-Fernandez R. Sossi V. Huang Z. G. Furtado S. Lu J. Q. Calne D. B. (2004). Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127 2747–2754. 10.1093/brain/awh290 15329355
Demarchi R. Bansal V. Hung A. Wroblewski K. Dua H. Sockalingam S. (2005). Review of Awakening Agents. Can. J. Neurol. Sci. 32 4–17.15825541
Dhamapurkar S. K. Wilson B. A. Rose A. Watson P. Shiel A. (2017). Does Modafinil improve the level of consciousness for people with a prolonged disorder of consciousness? a retrospective pilot study. Disabil. Rehabil. 39 2633–2639. 10.1080/09638288.2016.1236414 27793075
Doig N. M. Moss J. Bolam J. P. (2010). Cortical and Thalamic Innervation of Direct and Indirect Pathway Medium-Sized Spiny Neurons in Mouse Striatum. J. Neurosci. 30 :14610 . 10.1523/jneurosci.1623-10.2010 21048118
Donnemiller E. Brenneis C. Wissel J. Scherfler C. Poewe W. Riccabona G. (2000). Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using 123I-β-CIT and 123I-IBZM. Eur. J. Nuclear Med. 27 1410–1414. 10.1007/s002590000308 11007526
Dorer C. L. Manktelow A. E. Allanson J. Sahakian B. J. Pickard J. D. Bateman A. (2018). Methylphenidate-mediated motor control network enhancement in patients with traumatic brain injury. Brain Injury 32 1040–1049. 10.1080/02699052.2018.1469166 29738277
Dougherty S. E. Kajstura T. J. Jin Y. Chan-Cortés M. H. Kota A. Linden D. J. (2020). Catecholaminergic axons in the neocortex of adult mice regrow following brain injury. Exp. Neurol. 323 :113089 . 10.1016/j.expneurol.2019.113089 31697941
Dunn-Meynell A. Shijun P. Levin B. E. (1994). Focal traumatic brain injury causes widespread reductions in rat brain norepinephrine turnover from 6 to 24 h. Brain Res. 660 88–95. 10.1016/0006-8993(94)90842-7 7828006
Dunn-Meynell A. A. Levin B. E. (1997). Histological markers of neuronal, axonal and astrocytic changes after lateral rigid impact traumatic brain injury. Brain Res. 761 25–41. 10.1016/s0006-8993(97)00210-2 9247063
Duong J. Elia C. Takayanagi A. Lanzilotta T. Ananda A. Miulli D. (2018). The impact of methamphetamines in patients with traumatic brain injury, a retrospective review. Clin. Neurol. Neurosurg. 170 99–101. 10.1016/j.clineuro.2018.04.030 29763809
Eakin K. Hoffer B. Miller J. (2013). Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp. Neurol. 240 103–107. 10.1016/j.expneurol.2012.11.005 23153576
Ekinci O. Direk M. Ç Gunes S. Teke H. Ekinci N. Yıldırım F. (2017). Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems. Brain Dev. 39 327–336. 10.1016/j.braindev.2016.11.005 27903419
Ennis J. D. Harvey D. Ho E. Chari V. Graham A. Nesathurai S. (2013). Levodopa/carbidopa to improve motor function subsequent to brain tumor excision. Am. J. Phys. Med. Rehabil. 92 307–311. 10.1097/phm.0b013e318278dc20 23221674
Espadas M. Insa I. Chamorro M. Alda-Diez J. A. (2018). Efectos secundarios del metilfenidato en poblacion infantil y juvenil [Side effects of methylphenidate in children and the young]. Rev. Neurol. 66 157–162. 10.33588/rn.6605.2017480 29480512
Feeney D. M. Gonzalez A. Law W. A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217 855–857. 10.1126/science.7100929 7100929
Ferrada C. Ferre S. Casado V. Cortes A. Justinova Z. Barnes C. (2008). Interactions between histamine H-3 and dopamine D-2 receptors and the implications for striatal function. Neuropharmacology 55 190–197. 10.1016/j.neuropharm.2008.05.008 18547596
Ferrada C. Moreno E. Casado V. Bongers G. Cortes A. Mallol J. (2009). Marked changes in signal transduction upon heteromerization of dopamine D-1 and histamine H-3 receptors. Br. J. Pharm. 157 64–75. 10.1111/j.1476-5381.2009.00152.x 19413572
Ferré S. Bonaventura J. Tomasi D. Navarro G. Moreno E. Cortés A. (2016). Allosteric mechanisms within the adenosine A2A–dopamine D2 receptor heterotetramer. Neuropharmacology 104 154–160. 10.1016/j.neuropharm.2015.05.028 26051403
Ferré S. Ciruela F. (2019). Functional and Neuroprotective Role of Striatal Adenosine A(2A) Receptor Heterotetramers. J. Caffein. Adenos. Res. 9 89–97. 10.1089/caff.2019.0008 31559390
Flashman L. A. Mcdonald B. C. Ford J. C. Kenny R. M. Andrews K. D. Saykin A. J. (2021). Differential Effects of Pergolide and Bromocriptine on Working Memory Performance and Brain Activation after Mild Traumatic Brain Injury. J. Neurotrauma. 38 225–234.32635808
Folweiler K. A. Bondi C. O. Ogunsanya E. A. Laporte M. J. Leary J. B. Radabaugh H. L. (2017). Combining the Antipsychotic Drug Haloperidol and Environmental Enrichment after Traumatic Brain Injury Is a Double-Edged Sword. J. Neurotrauma. 34 451–458. 10.1089/neu.2016.4417 26975872
Frenette A. J. Kanji S. Rees L. Williamson D. R. Perreault M. M. Turgeon A. F. (2011). Efficacy and Safety of Dopamine Agonists in Traumatic Brain Injury: A Systematic Review of Randomized Controlled Trials. J. Neurotrauma. 29 1–18. 10.1089/neu.2011.1812 21846248
Frenette A. J. Kanji S. Rees L. Williamson D. R. Perreault M. M. Turgeon A. F. (2012). Efficacy and Safety of Dopamine Agonists in Traumatic Brain Injury: A Systematic Review of Randomized Controlled Trials. J. Neurotrauma. 29 1–18. 10.1089/neu.2011.1812 21846248
Freund T. F. Powell J. F. Smith A. D. (1984). Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13 1189–1215. 10.1016/0306-4522(84)90294-x 6152036
Fridman E. A. Krimchansky B. Z. Bonetto M. Galperin T. Gamzu E. R. Leiguarda R. C. (2010). Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 24 636–641. 10.3109/02699051003610433 20235766
Fridman E. A. Osborne J. R. Mozley P. D. Victor J. D. Schiff N. D. (2019). Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury. Brain 142 1887–1893. 10.1093/brain/awz118 31505542
Fundament T. Eldridge P. R. Green A. L. Whone A. L. Taylor R. S. Williams A. C. (2016). Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PLoS One 2016 :11 .
Fuxe K. Marcellino D. Borroto-Escuela D. O. Guescini M. Fernández-Dueñas V. Tanganelli S. (2010). Adenosine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders. CNS Neurosci. Therapeut. 16 e18–e42.
Fuxe K. Marcellino D. Rivera A. Diaz-Cabiale Z. Filip M. Gago B. (2008). Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 58 415–452. 10.1016/j.brainresrev.2007.11.007 18222544
Gálvez-Rosas A. Avila-Luna A. Valdés-Flores M. Montes S. Bueno-Nava A. (2019). GABAergic imbalance is normalized by dopamine D1 receptor activation in the striatum contralateral to the cortical injury in motor deficit-recovered rats. Psychopharmacology 236 :5215 .
Gao Y. Ma L. Liang F. Zhang Y. Yang L. Liu X. (2020). The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage. Brain Inj. 34 1084–1088. 10.1080/02699052.2020.1780315 32552090
Garcia M. Floran B. Arias-Montano J. A. Young J. M. Aceves J. (1997). Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 80 241–249. 10.1016/s0306-4522(97)00100-0 9252235
Gaspar P. Bloch B. Le Moine C. (1995). D1 and D2 Receptor Gene Expression in the Rat Frontal Cortex: Cellular Localization in Different Classes of Efferent Neurons. Eur. J. Neurosci. 7 1050–1063. 10.1111/j.1460-9568.1995.tb01092.x 7613610
Gee S. Ellwood I. Patel T. Luongo F. Deisseroth K. Sohal V. S. (2012). Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J. Neurosci. 32 4959–4971. 10.1523/jneurosci.5835-11.2012 22492051
Gerfen C. R. Surmeier D. J. (2011). Modulation of Striatal Projection Systems by Dopamine. Ann. Rev. Neurosci. 34 441–466. 10.1146/annurev-neuro-061010-113641 21469956
Ghalaenovi H. Fattahi A. Koohpayehzadeh J. Khodadost M. Fatahi N. Taheri M. (2018). The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj. 32 1050–1055. 10.1080/02699052.2018.1476733 29790790
Ghate P. S. Bhanage A. Sarkar H. Katkar A. (2018). Efficacy of Amantadine in Improving Cognitive Dysfunction in Adults with Severe Traumatic Brain Injury in Indian Population: A Pilot Study. Asian J. Neurosurg. 13 647–650.30283519
Giacino J. T. Whyte J. Bagiella E. Kalmar K. Childs N. Khademi A. (2012). Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. N. Engl. J. Med. 366 819–826.22375973
Gramish J. A. Kopp B. J. Patanwala A. E. (2017). Effect of Amantadine on Agitation in Critically Ill Patients With Traumatic Brain Injury. Clin. Neuropharm. 2017 :40 .
Greengard P. Allen P. B. Nairn A. C. (1999). Beyond the Dopamine Receptor: the DARPP-32/Protein Phosphatase-1 Cascade. Neuron 23 435–447.10433257
Guerriero R. M. Giza C. C. Rotenberg A. (2015). Glutamate and GABA Imbalance Following Traumatic Brain Injury. Curr. Neurol. Neurosci. Rep. 2015 :15 .
Guigoni C. Aubert I. Li Q. Gurevich V. V. Benovic J. L. Ferry S. (2005). Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinson. Relat. Dis. 11 S25–S29.
Haber S. N. (2016). Corticostriatal circuitry. Dial. Clin. Neurosci. 18 7–21. 10.31887/dcns.2016.18.1/shaber 27069376
Hadgu R. M. Borghol A. Gillard C. Wilson C. Elqess Mossa S. Mckay M. (2020). Evaluation of Outcomes in Patients Receiving Amantadine to Improve Alertness After Traumatic Brain Injury. Hospital Pharm. 0 :0018578720920803 .
Hammond F. M. Malec J. F. Zafonte R. D. Sherer M. Bogner J. Dikmen S. (2017). Potential Impact of Amantadine on Aggression in Chronic Traumatic Brain Injury. J. Head Traum. Rehabilit. 32 308–318. 10.1097/htr.0000000000000342 28891908
Harmon R. L. Boyeson M. G. (1997). Clinical Neuropharmacology of Behavioral Recovery Following Brain Injury. Phys. Med. Rehabilit. Clin. North Am. 8 651–665. 10.1016/s1047-9651(18)30295-x
Hersch S. M. Yi H. Heilman C. J. Edwards R. H. Levey A. I. (1997). Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388 211–227. 10.1002/(sici)1096-9861(19971117)388:2<211::aid-cne3>3.0.co;2-4 9368838
Horn S. D. Corrigan J. D. Dijkers M. P. (2015). Traumatic Brain Injury Rehabilitation Comparative Effectiveness Research: Introduction to the Traumatic Brain-Practice Based Evidence Archives Supplement. Archiv. Phys. Med. Rehabilit. 96 S173–S177.
Hovda D. A. Sutton R. L. Feeney D. M. (1987). Recovery of tactile placing after visual cortex ablation in cat: A behavioral and metabolic study of diaschisis. Exp. Neurol. 97 391–402. 10.1016/0014-4886(87)90099-9 3038589
Hsu K. S. Huang C. C. Yang C. H. Gean P. W. (1995). Presynaptic D-2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res. 690 264–268. 10.1016/0006-8993(95)00734-8 8535848
Huang E. Y.-K. Tsai T.-H. Kuo T.-T. Tsai J. Jr. Tsui P.-F. Chou Y.-C. (2014a). Remote effects on the striatal dopamine system after fluid percussion injury. Behav. Brain Res. 267 156–172. 10.1016/j.bbr.2014.03.033 24675161
Huang E. Y.-K. Tsui P.-F. Kuo T.-T. Tsai J. Jr. Chou Y.-C. Ma H.-I. (2014b). Amantadine Ameliorates Dopamine-Releasing Deficits and Behavioral Deficits in Rats after Fluid Percussion Injury. PLoS One 9 :e86354 . 10.1371/journal.pone.0086354 24497943
Huang Y.-N. Yang L.-Y. Greig N. H. Wang Y.-C. Lai C.-C. Wang J.-Y. (2018). Neuroprotective effects of pifithrin-α against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. Sci. Rep. 8 2368–2368.29402897
Huger F. Patrick G. (1979). EFFECT OF CONCUSSIVE HEAD INJURY ON CENTRAL CATECHOLAMINE LEVELS AND SYNTHESIS RATES IN RAT BRAIN REGIONS 1. J. Neurochem. 33 89–95. 10.1111/j.1471-4159.1979.tb11710.x 458474
Humbert-Claude M. Morisset S. Gbahou F. Arrang J.-M. (2007). Histamine H3 and dopamine D2 receptor-mediated [35S]GTPγ[S] binding in rat striatum: Evidence for additive effects but lack of interactions. Biochem. Pharm. 73 1172–1181. 10.1016/j.bcp.2007.01.006 17306767
Hutson C. B. Lazo C. R. Mortazavi F. Giza C. C. Hovda D. Chesselet M.-F. (2011). Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J. Neurot. 28 1783–1801. 10.1089/neu.2010.1723 21644813
Iaccarino M. A. Philpotts L. L. Zafonte R. Biederman J. (2020). Stimulant Use in the Management of Mild Traumatic Brain Injury: A Qualitative Literature Review. J. Attent. Dis. 24 309–317. 10.1177/1087054718759752 29519208
Jackson D. M. Westlind-Danielsson A. (1994). Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharm. Therap. 64 291–370. 10.1016/0163-7258(94)90041-8
Jang S. H. Kim S. H. Seo J. P. (2018). Recovery of an injured corticofugal tract from the supplementary motor area in a patient with traumatic brain injury: A case report. Medicine 97 e9063–e9063.29443731
Jenkins P. O. De Simoni S. Bourke N. J. Fleminger J. Scott G. Towey D. J. (2018). Dopaminergic abnormalities following traumatic brain injury. Brain 141 797–810.29360949
Jenkins P. O. Mehta M. A. Sharp D. J. (2016). Catecholamines and cognition after traumatic brain injury. Brain 139 2345–2371. 10.1093/brain/aww128 27256296
Johansson B. Wentzel A.-P. Andréll P. Rönnbäck L. Mannheimer C. (2017). Long-term treatment with methylphenidate for fatigue after traumatic brain injury. Acta Neurol. Scand. 135 100–107. 10.1111/ane.12587 26991608
Johansson B. Wentzel A. P. Andréll P. Mannheimer C. Rönnbäck L. (2015). Methylphenidate reduces mental fatigue and improves processing speed in persons suffered a traumatic brain injury. Brain Inj. 29 758–765. 10.3109/02699052.2015.1004747 25794299
Jolly A. E. Raymont V. Cole J. H. Whittington A. Scott G. De Simoni S. (2019). Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression. NeuroImage Clin. 24 :101950 . 10.1016/j.nicl.2019.101950 31352218
Jones E. A. Wang J. Q. Mcginty J. F. (2001). Intrastriatal GABAA receptor blockade does not alter dopamine D1/D2 receptor interactions in the intact rat striatum. Neuroscience 102 381–389. 10.1016/s0306-4522(00)00451-6 11166124
Kaelin D. L. Cifu D. X. Matthies B. (1996). Methylphenidate effect on attention deficit in the acutely brain-injured adult. Archiv. Phys. Med. Rehabilit. 77 6–9. 10.1016/s0003-9993(96)90211-7
Kaiser P. R. Valko P. O. Werth E. Thomann J. Meier J. Stocker R. (2010). Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology 75 1780–1785. 10.1212/wnl.0b013e3181fd62a2 21079179
Kandel E. R. Schwartz J. H. Jessell T. M. Siegelbaum S. A. Hudspeth A. J. (2013). Principles of Neural Science. Chennai: McGraw Hill Education.
Karelina K. Gaier K. R. Weil Z. M. (2017). Traumatic brain injuries during development disrupt dopaminergic signaling. Exp. Neurol. 297 110–117. 10.1016/j.expneurol.2017.08.003 28802560
Keeler J. F. Pretsell D. O. Robbins T. W. (2014). Functional implications of dopamine D1 vs. D2 receptors: a ‘prepare and select’ model of the striatal direct vs. Indirect pathways. Neuroscience 282 156–175. 10.1016/j.neuroscience.2014.07.021 25062777
Kemp J. M. Powell T. P. S. Harris G. W. (1971). The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method. Philosop. Transac. R. Soc. Lond. B Biol. Sci. 262 429–439. 10.1098/rstb.1971.0105 4107496
Kerkerian L. Dusticier N. Nieoullon A. (1987). Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J. Neurochem. 48 1301–1306. 10.1111/j.1471-4159.1987.tb05661.x 2880932
Kernie S. G. Parent J. M. (2010). Forebrain neurogenesis after focal Ischemic and traumatic brain injury. Neurob. Dis. 37 267–274. 10.1016/j.nbd.2009.11.002 19909815
Kline A. E. Chen M. J. Tso-Olivas D. Y. Feeney D. M. (1994). Methylphenidate treatment following ablation-induced hemiplegia in rat: Experience during drug action alters effects on recovery of function. Pharm. Biochem. Behav. 48 773–779. 10.1016/0091-3057(94)90345-x
Kline A. E. Massucci J. L. Ma X. Zafonte R. D. Edward Dixon C. (2004). Bromocriptine Reduces Lipid Peroxidation and Enhances Spatial Learning and Hippocampal Neuron Survival in a Rodent Model of Focal Brain Trauma. J. Neurot. 21 1712–1722. 10.1089/neu.2004.21.1712 15684763
Kline A. E. Yan H. Q. Bao J. Marion D. W. Dixon C. E. (2000). Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neurosci. Lett. 280 163–166. 10.1016/s0304-3940(00)00797-7 10675786
Ko I.-G. Kim C.-J. Kim H. (2019). Treadmill exercise improves memory by up-regulating dopamine and down-regulating D(2) dopamine receptor in traumatic brain injury rats. J. Exer. Rehabilit. 15 504–511. 10.12965/jer.1938316.158 31523669
Koshimizu Y. Fujiyama F. Nakamura K. C. Furuta T. Kaneko T. (2013). Quantitative analysis of axon bouton distribution of subthalamic nucleus neurons in the rat by single neuron visualization with a viral vector. J. Comp. Neurol. 521 2125–2146. 10.1002/cne.23277 23595816
Kreitzer A. C. Malenka R. C. (2008). Striatal Plasticity and Basal Ganglia Circuit Function. Neuron 60 543–554. 10.1016/j.neuron.2008.11.005 19038213
Krimchansky B.-Z. Keren O. Sazbon L. Groswasser Z. (2004). Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Inj. 18 1099–1105. 10.1080/02699050310001646206 15545207
Krobert K. A. Sutton R. L. Feeney D. M. (1994). Spontaneous and amphetamine-evoked release of cerebellar noradrenaline after sensorimotor cortex contusion: an in vivo microdialysis study in the awake rat. J. Neurochem. 62 2233–2240. 10.1046/j.1471-4159.1994.62062233.x 8189231
Kupferschmidt D. A. Juczewski K. Cui G. Johnson K. A. Lovinger D. M. (2017). Parallel, but Dissociable, Processing in Discrete Corticostriatal Inputs Encodes Skill Learning. Neuron 96 476.e–489.e.29024667
L’hirondel M. Chéramy A. Godeheu G. Artaud F. Saiardi A. Borrelli E. (1998). Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res. 792 253–262. 10.1016/s0006-8993(98)00146-2 9593923
Lal S. Merbtiz C. P. Grip J. C. (1988). Modification of function in head-injured patients with Sinemet. Brain Inj. 2 225–233. 10.3109/02699058809150946 2458792
Lan Y. L. Li S. Lou J. C. Ma X. C. Zhang B. (2019). The potential roles of dopamine in traumatic brain injury: a preclinical and clinical update. Am. J. Transl. Res. 11 2616–2631.31217842
Langley K. C. Bergson C. Greengard P. Ouimet C. C. (1997). Co-localization of the D1 dopamine receptor in a subset of DARPP-32-containing neurons in rat caudate–putamen. Neuroscience 78 977–983. 10.1016/s0306-4522(96)00583-0 9174066
Le Moine C. Bloch B. (1995). D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comparat. Neurol. 355 418–426. 10.1002/cne.903550308 7636023
Leergaard T. B. (2003). Clustered and laminar topographic patterns in rat cerebro-pontine pathways. Anat. Embryol. 206 149–162. 10.1007/s00429-002-0272-7 12592566
Lei W. L. Jiao Y. Del Mar N. Reiner A. (2004). Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J. Neurosci. 24 8289–8299. 10.1523/jneurosci.1990-04.2004 15385612
Levin B. E. Brown K. L. Pawar G. Dunn-Meynell A. (1995). Widespread and lateralized effects of acute traumatic brain injury on norepinephrine turnover in the rat brain. Brain Res. 674 307–313. 10.1016/0006-8993(95)00032-l 7796111
Leyrer-Jackson J. M. Thomas M. P. (2017). Subtype-specific effects of dopaminergic D2 receptor activation on synaptic trains in layer V pyramidal neurons in the mouse prefrontal cortex. Physiolog. Rep. 5 :e13499 . 10.14814/phy2.13499 29150590
Liao R. Chen Y. Cheng L. Fan L. Chen H. Wan Y. (2019). Histamine H1 Receptors in Neural Stem Cells Are Required for the Promotion of Neurogenesis Conferred by H3 Receptor Antagonism following Traumatic Brain Injury. Stem Cell Rep. 12 532–544. 10.1016/j.stemcr.2019.01.004 30745032
Lidow M. S. Goldmanrakic P. S. Gallager D. W. Rakic P. (1991). Distribution of dopaminergic receptors in the primate cerebral-cortex - quantitative autoradiographic analysis using 3H raclopride, 3H spiperone and 3H SCH23390. Neuroscience 40 657–671. 10.1016/0306-4522(91)90003-7 2062437
Lieberman A. N. Goldstein M. (1985). Bromocriptine in Parkinson disease. Pharm. Rev. 37 217 .
Liepert J. (2008). Pharmacotherapy in restorative neurology. Curr. Opin. Neurol. 2008 :21 .
Loane D. J. Kumar A. (2016). Microglia in the TBI brain: The good, the bad, and the dysregulated. Exp. Neurol. 275 316–327. 10.1016/j.expneurol.2015.08.018 26342753
Lodge D. J. Grace A. A. (2011). Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharm. Sci. 32 507–513. 10.1016/j.tips.2011.05.001 21700346
Loggini A. Tangonan R. El Ammar F. Mansour A. Goldenberg F. D. Kramer C. L. (2020). The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review. Clin. Neurol. Neurosurg. 194 :105815 . 10.1016/j.clineuro.2020.105815 32244036
López De Maturana R. Sánchez-Pernaute R. (2010). Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors. CNSNeurol. Dis. Drug Targ. 9 601–615. 10.2174/187152710793361531 20632967
Lu L. Li F. Ma Y. Chen H. Wang P. Peng M. (2019). Functional connectivity disruption of the substantia nigra associated with cognitive impairment in acute mild traumatic brain injury. Eur. J. Radiol. 114 69–75. 10.1016/j.ejrad.2019.03.002 31005180
Ma H. M. Zafonte R. D. (2020). Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Inj. 34 299–315. 10.1080/02699052.2020.1723697 32078407
Manktelow A. E. Menon D. K. Sahakian B. J. Stamatakis E. A. (2017). Working Memory after Traumatic Brain Injury: The Neural Basis of Improved Performance with Methylphenidate. Front. Behav. Neurosci. 2017 :11 .
Marcellino D. Ferré S. Casadó V. Cortés A. Le Foll B. Mazzola C. (2008). Identification of Dopamine D1–D3 Receptor Heteromers: indications for a role of synergistic d1–d3 receptor interactions in the striatum∗. J. Biol. Chem. 283 26016–26025.18644790
Massucci J. L. Kline A. E. Ma X. Zafonte R. D. Dixon C. E. (2004). Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci. Lett. 372 127–131. 10.1016/j.neulet.2004.09.026 15531102
Mathai A. Smith Y. (2011). The Corticostriatal and Corticosubthalamic Pathways: Two Entries, One Target. So What? Front. Syst. Neurosci. 5 1–10.21347218
Matsuda W. Komatsu Y. Yanaka K. Matsumura A. (2005). Levodopa treatment for patients in persistent vegetative or minimally conscious states. Neuropsychol. Rehabilit. 15 414–427. 10.1080/09602010443000588 16350982
Mcallister T. W. Mcdonald B. C. Ferrell R. B. Tosteson T. D. Yanofsky N. N. Grove M. R. (2011). Dopaminergic challenge with bromocriptine one month after mild traumatic brain injury: altered working memory and BOLD response. J. Neuropsychiat. Clin. Neurosci. 23 277–286. 10.1176/jnp.23.3.jnp277 21948888
Mendoza G. Merchant H. (2014). Motor system evolution and the emergence of high cognitive functions. Prog. Neurobiol. 122 73–93. 10.1016/j.pneurobio.2014.09.001 25224031
Menon D. K. Schwab K. Wright D. W. Maas A. I. Int Interagency Initiative C. (2010). Position Statement: Definition of Traumatic Brain Injury. Archiv. Phys. Med. Rehabilit. 91 1637–1640. 10.1016/j.apmr.2010.05.017 21044706
Meschler J. P. Howlett A. C. (2001). Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40 918–926. 10.1016/s0028-3908(01)00012-0 11378162
Meythaler J. M. Brunner R. C. Johnson A. Novack T. A. (2002). Amantadine to Improve Neurorecovery in Traumatic Brain Injury–Associated Diffuse Axonal Injury: A Pilot Double-blind Randomized Trial. J. Head Trauma Rehabilit. 17 300–313. 10.1097/00001199-200208000-00004 12105999
Missale C. Nash S. R. Robinson S. W. Jaber M. Caron M. G. (1998). Dopamine receptors: from structure to function. Physiolog. Rev. 78 189–225.
Moreno E. Hoffmann H. Gonzalez-Sepulveda M. Navarro G. Casado V. Cortes A. (2011). Dopamine D-1-histamine H-3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. J. Biolog. Chem. 286 5846–5854. 10.1074/jbc.m110.161489 21173143
Muly E. C. Szigeti K. Goldman-Rakic P. S. (1998). D1 receptor in interneurons of macaque prefrontal cortex: Distribution and subcellular localization. J. Neurosci. 18 10553–10565. 10.1523/jneurosci.18-24-10553.1998 9852592
Munakomi S. Bhattarai B. Mohan Kumar B. (2017). Role of bromocriptine in multi-spectral manifestations of traumatic brain injury. Chin. J. Traumatol. 20 84–86. 10.1016/j.cjtee.2016.04.009 28325648
Neely M. D. Schmidt D. E. Deutch A. Y. (2007). Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience 149 457–464. 10.1016/j.neuroscience.2007.06.044 17888581
Ng S. Y. Lee A. Y. W. (2019). Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets. Front. Cell. Neurosci. 2019 :13 .
Okigbo A. A. Helkowski M. S. Royes B. J. Bleimeister I. H. Lam T. R. Bao G. C. (2019). Dose-dependent neurorestorative effects of amantadine after cortical impact injury. Neurosci. Lett. 694 69–73. 10.1016/j.neulet.2018.11.030 30472358
Osier N. D. Dixon C. E. (2016a). Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 1640 15–35. 10.1016/j.brainres.2015.12.026 26711850
Osier N. D. Dixon C. E. (2016b). The Controlled Cortical Impact Model: Applications, Considerations for Researchers, and Future Directions. Front. Neurol. 2016 :7 .
Otero Villaverde S. Martin Mourelle R. Crespo Lopez C. Cabrera Sarmiento J. J. Ruiz Castillo A. Canosa Hermida E. (2019). Uso de bromocriptina en pacientes con alteración de conciencia secundaria a traumatismo craneoencefálico [Bromocriptine in disorders of consciouness due to traumatic brain injury]. Rehabilitacion 53 155–161. 10.1016/j.rh.2019.03.001 31370942
Ozga J. E. Povroznik J. M. Engler-Chiurazzi E. B. Vonder Haar C. (2018). Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology. Behav. Pharm. 29 617–637. 10.1097/fbp.0000000000000430 30215621
Park E. Ai J. Baker A. J. (2007). “Cerebellar injury: clinical relevance and potential in traumatic brain injury research,” in Progress in Brain Research, eds Weber J. T. Maas A. I. R. (Amsterdam: Elsevier), 327–338. 10.1016/s0079-6123(06)61023-6
Passler M. A. Riggs R. V. (2001). Positive outcomes in traumatic brain injury–vegetative state: Patients treated with bromocriptine. Archiv. Phys. Med. Rehabilit. 82 311–315. 10.1053/apmr.2001.20831 11245751
Phelps T. I. Bondi C. O. Ahmed R. H. Olugbade Y. T. Kline A. E. (2015). Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits. J. Neurot. 32 590–597. 10.1089/neu.2014.3711 25275833
Phelps T. I. Bondi C. O. Mattiola V. V. Kline A. E. (2017). Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma. Neurorehabil. Neural. Repair. 31 25–33. 10.1177/1545968316650281 27225976
Plummer N. R. Tam A. W. F. Mulvaney C. A. Preston N. J. Laha S. K. (2018). Dopamine agonists for traumatic brain injury. Cochrane Database Syst. Rev. 2018 :CD013062 .
Polich G. Iaccarino M. A. Zafonte R. (2019). Psychopharmacology of traumatic brain injury. Handb. Clin. Neurol. 165 253–267. 10.1016/b978-0-444-64012-3.00015-0 31727216
Primus E. A. Bigler E. D. Anderson C. V. Johnson S. C. Mueller R. M. Blatter D. (1997). Corpus striatum and traumatic brain injury. Brain Inj. 11 577–586. 10.1080/026990597123278 9251866
Rangel-Barajas C. Coronel I. Floran B. (2015). Dopamine Receptors and Neurodegeneration. Aging and Disease 6 349–368. 10.14336/ad.2015.0330 26425390
Rapanelli M. (2017). The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry. Prog. Neuro-Psychopharm. Biol. Psychiatr. 73 36–40. 10.1016/j.pnpbp.2016.10.002 27773554
Rapanelli M. Frick L. R. Horn K. D. Schwarcz R. C. Pogorelov V. Nairn A. C. (2016). The Histamine H3 Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons. J. Biol. Chem. 291 21042–21052. 10.1074/jbc.m116.731406 27510032
Rau T. Ziemniak J. Poulsen D. (2016). The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury. Prog. Neuro-Psychopharm. Biol. Psychiatr. 64 231–236. 10.1016/j.pnpbp.2015.02.013 25724762
Reddy C. C. Collins M. Lovell M. Kontos A. P. (2013). Efficacy of Amantadine Treatment on Symptoms and Neurocognitive Performance Among Adolescents Following Sports-Related Concussion. J. Head Trauma Rehabilitat. 2013 :28 .
Reep R. L. Cheatwood J. L. Corwin J. V. (2003). The associative striatum: Organization of cortical projections to the dorsocentral striatum in rats. J. Comparat. Neurol. 467 271–292. 10.1002/cne.10868 14608594
Reep R. L. Corwin J. V. (1999). Topographic organization of the striatal and thalamic connections of rat medial agranular cortex. Brain Res. 841 43–52. 10.1016/s0006-8993(99)01779-5 10546986
Reiner A. Hart N. M. Lei W. L. Deng Y. P. (2010). Corticostriatal projection neurons - dichotomous types and dichotomous functions. Front. Neuroanat. 4 1–15. 10.1007/978-3-7643-8732-7_1 20161990
Repantis D. Bovy L. Ohla K. Kühn S. Dresler M. (2021). Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine. Psychopharmacology 238 441–451. 10.1007/s00213-020-05691-w 33201262
Sanchez-Lemus E. Arias-Montano J. A. (2004). Histamine H-3 receptor activation inhibits dopamine D-1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci. Lett. 364 179–184. 10.1016/j.neulet.2004.04.045 15196671
Santana N. Artigas F. (2017). Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex. Front. Neuroanat. 11 :87–87.29033796
Sawyer E. Maura L. S. Ohlinger M. J. (2008). Amantadine Enhancement of Arousal and Cognition After Traumatic Brain Injury. Ann. Pharmacother. 42 247–252. 10.1345/aph.1k284 18212258
Schmitz Y. Benoit-Marand M. Gonon F. Sulzer D. (2003). Presynaptic regulation of dopaminergic neurotransmission. J. Neurochem. 87 273–289. 10.1046/j.1471-4159.2003.02050.x 14511105
Schmitz Y. Schmauss C. Sulzer D. (2002). Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J. Neurosci. 22 8002–8009. 10.1523/jneurosci.22-18-08002.2002 12223553
Schonfeld L. M. Dooley D. Jahanshahi A. Temel Y. Hendrix S. (2017). Evaluating rodent motor functions: Which tests to choose? Neurosci. Biobehav. Rev. 83 298–312. 10.1016/j.neubiorev.2017.10.021 29107829
Seniów J. Litwin M. Litwin T. Leśniak M. Członkowska A. (2009). New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J. Neurolog. Sci. 283 214–218. 10.1016/j.jns.2009.02.336 19268976
Shepherd G. M. G. (2013). Corticostriatal connectivity and its role in disease. Nat. Rev. Neurosci. 14 278 . 10.1038/nrn3469 23511908
Shi K. Zhang J. Dong J.-F. Shi F.-D. (2019). Dissemination of brain inflammation in traumatic brain injury. Cell. Mole. Immunol. 16 :1 .
Shin S. S. Bray E. R. Zhang C. Q. Dixon C. E. (2011). Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats. Brain Res. 1369 208–215. 10.1016/j.brainres.2010.10.096 21047500
Shipp S. (2017). The functional logic of corticostriatal connections. Brain Struct. Funct. 222 669–706. 10.1007/s00429-016-1250-9 27412682
Silberberg G. Bolam J. P. (2015). Local and afferent synaptic pathways in the striatal microcircuitry. Curr. Opin. Neurobiol. 33 182–187. 10.1016/j.conb.2015.05.002 26051382
Smith Y. Parent A. (1986). Differential connections of caudate nucleus and putamen in the squirrel monkey (Saimiri sciureus). Neuroscience 18 347–371. 10.1016/0306-4522(86)90159-4 3736862
Smith Y. Raju D. V. Pare J. F. Sidibe M. (2004). The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 27 520–527. 10.1016/j.tins.2004.07.004 15331233
Spritzer S. D. Kinney C. L. Condie J. Wellik K. E. Hoffman-Snyder C. R. Wingerchuk D. M. (2015). Amantadine for Patients With Severe Traumatic Brain Injury: A Critically Appraised Topic. Neurologist 19 61–64. 10.1097/nrl.0000000000000001 25607336
Sunahara R. K. Guan H. C. O’dowd B. F. Seeman P. Laurier L. G. Ng G. (1991). Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350 614–619. 10.1038/350614a0 1826762
Surmeier D. J. Ding J. Day M. Wang Z. Shen W. (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30 228–235. 10.1016/j.tins.2007.03.008 17408758
Surmeier D. J. Song W. J. Yan Z. (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16 6579–6591. 10.1523/jneurosci.16-20-06579.1996 8815934
Ter Mors B. J. Backx A. P. M. Spauwen P. Ponds R. W. H. M. Van Harten P. N. Van Heugten C. M. (2019). Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review. Brain Inj. 33 1137–1150. 10.1080/02699052.2019.1631482 31250669
Traeger J. Hoffman B. Misencik J. Hoffer A. Makii J. (2020). Pharmacologic Treatment of Neurobehavioral Sequelae Following Traumatic Brain Injury. Crit. Care Nurs. Q. 2020 :43 .
Treble-Barna A. Wade S. L. Martin L. J. Pilipenko V. Yeates K. O. Taylor H. G. (2017). Influence of Dopamine-Related Genes on Neurobehavioral Recovery after Traumatic Brain Injury during Early Childhood. J. Neurotr. 34 1919–1931. 10.1089/neu.2016.4840 28323555
Tsuda S. Golam M. Hou J. Nelson R. Bernavil P. Richardson K. (2020). Altered monoaminergic levels, spasticity, and balance disability following repetitive blast-induced traumatic brain injury in rats. Brain Res. 1747 147060 . 10.1016/j.brainres.2020.147060 32828734
Undieh A. S. (2010). Pharmacology of signaling induced by dopamine D-1-like receptor activation. Pharm. Ther. 128 37–60. 10.1016/j.pharmthera.2010.05.003 20547182
Valjent E. Bertran-Gonzalez J. Herve D. Fisone G. Girault J.-A. (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci. 32 538–547. 10.1016/j.tins.2009.06.005 19765834
Vallone D. Picetti R. Borrelli E. (2000). Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 24 125–132.10654668
Van Bregt D. R. Thomas T. C. Hinzman J. M. Cao T. Liu M. Bing G. (2012). Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp. Neurol. 234 8–19. 10.1016/j.expneurol.2011.12.003 22178300
Van Tol H. H. Bunzow J. R. Guan H. C. Sunahara R. K. Seeman P. Niznik H. B. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350 610–614. 10.1038/350610a0 1840645
Van Vleet T. M. Heldt S. A. Pyter B. Corwin J. V. Reep R. L. (2003). Effects of light deprivation on recovery from neglect and extinction induced by unilateral lesions of the medial agranular cortex and dorsocentral striatum. Behav. Brain Res. 138 165–178. 10.1016/s0166-4328(02)00246-2 12527447
Wagner A. K. Chen X. B. Kline A. E. Li Y. M. Zafonte R. D. Dixon C. E. (2005a). Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury. Exp. Neurol. 195 475–483. 10.1016/j.expneurol.2005.06.009 16023635
Wagner A. K. Kline A. E. Ren D. Willard L. A. Wenger M. K. Zafonte R. D. (2007). Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury. Behav. Brain Res. 181 200–209. 10.1016/j.bbr.2007.04.006 17517440
Wagner A. K. Scanlon J. M. Becker C. R. Ritter A. C. Niyonkuru C. Dixon C. E. (2014). The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI. J. Cereb. Blood flow Metab. 34 1328–1339. 10.1038/jcbfm.2014.87 24849661
Wagner A. K. Sokoloski J. E. Ren D. Chen X. Khan A. S. Zafonte R. D. (2005b). Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J. Neurochem. 95 457–465. 10.1111/j.1471-4159.2005.03382.x 16190869
Wang Y. H. Zhou F. M. (2017). Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation. Front. Pharm. 8 1–13.
Warden D. L. Gordon B. Mcallister T. W. Silver J. M. Barth J. T. Bruns J. (2006). Guidelines for the Pharmacologic Treatment of Neurobehavioral Sequelae of Traumatic Brain Injury. J. Neurot. 23 1468–1501.
Weber P. Lütschg J. (2002). Methylphenidate treatment. Pediatr. Neurol. 26 261–266. 10.1016/s0887-8994(01)00408-8 11992752
Whyte J. Hart T. Vaccaro M. Grieb-Neff P. Risser A. Polansky M. (2004). Effects of Methylphenidate on Attention Deficits After Traumatic Brain Injury: A Multidimensional, Randomized, Controlled Trial. Am. J. Phys. Med. Rehabilit. 2004 :83 .
Whyte J. Vaccaro M. Grieb-Neff P. Hart T. Polansky M. Coslett H. B. (2008). The Effects of Bromocriptine on Attention Deficits After Traumatic Brain Injury: A Placebo-Controlled Pilot Study. Am. J. Phys. Med. Rehabilit. 87 85–99. 10.1097/phm.0b013e3181619609 18209510
Wickens J. R. Wilson C. J. (1998). Regulation of action-potential firing in spiny neurons of the rat neostriatum in vivo. J. Neurophys. 79 2358–2364. 10.1152/jn.1998.79.5.2358 9582211
Wiley C. A. Bissel S. J. Lesniak A. Dixon C. E. Franks J. Stolz D. B. (2016). Ultrastructure of Diaschisis Lesions after Traumatic Brain Injury. J. Neurotr. 33 1866–1882. 10.1089/neu.2015.4272 26914973
Williamson D. Frenette A. J. Burry L. D. Perreault M. Charbonney E. Lamontagne F. (2019). Pharmacological interventions for agitated behaviours in patients with traumatic brain injury: a systematic review. BMJ Open 9 e029604 . 10.1136/bmjopen-2019-029604 31289093
Wortzel H. S. Arciniegas D. B. (2012). Treatment of Post-Traumatic Cognitive Impairments. Curr. Treat. Option. Neurol. 14 493–508. 10.1007/s11940-012-0193-6 22865461
Wouterlood F. G. Van Oort S. Bloemhard L. Flierman N. A. Spijkerman J. Wright C. I (2018). Neurochemical fingerprinting of amygdalostriatal and intra-amygdaloid projections: a tracing–immunofluorescence study in the rat. J. Chem. Neuroanat. 94 154–172. 10.1016/j.jchemneu.2018.11.001 30412707
Wu J. H. Corwin J. V. Reep R. L. (2009). Organization of the corticostriatal projection from rat medial agranular cortex to far dorsolateral striatum. Brain Res. 1280 69–76. 10.1016/j.brainres.2009.05.044 19465007
Wu T. S. Garmel G. M. (2005). Improved neurological function after Amantadine treatment in two patients with brain injury. J. Emer. Med. 28 289–292. 10.1016/j.jemermed.2004.11.016 15769570
Yan H. Q. Ma X. Chen X. Li Y. Shao L. Dixon C. E. (2007). Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury. Brain Res. 1134 171–179. 10.1016/j.brainres.2006.11.087 17196177
Yoshida S. T. Baella S. A. Stuebner N. M. Crawford C. A. Mcdougall S. A. (2006). Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats. Brain Res. 1073-1074 269–275. 10.1016/j.brainres.2005.12.054 16427034
Zakhary T. Sabry A. (2017). Bromocriptine in Central Hyperthermia after Severe Traumatic Brain Injury. Open J. Emer. Med. 5 102–110. 10.4236/ojem.2017.53010
Zhang W.-T. Wang Y.-F. (2017). Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury. Medicine 96 :e6960 . 10.1097/md.0000000000006960 28640076

